Gardner Lewis Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Gardner Lewis Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-13,187	Closed	-$1.03M	–	114
2016 Q2	$1.03M	Buy	+13,187	New	+$1.12M	0.11%	89

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gardner Lewis Asset Management's BMRN Position: Q3 2016 in Review

Gardner Lewis Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2016, closing a stake of 13,187 shares — an estimated $1.03M sold.

Gardner Lewis Asset Management first reported a position in BMRN in Q2 2016 and held it in 1 quarter. The position peaked at $1.03M in Q2 2016. 422 funds tracked by Wall St. Rank hold BMRN as of Q3 2016.

Gardner Lewis Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Gardner Lewis Asset Management sold 13,187 BioMarin Pharmaceuticals shares in Q3 2016, an estimated $1.03M.
Gardner Lewis Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2016 and held it in 1 quarter.
Gardner Lewis Asset Management's BioMarin Pharmaceuticals position peaked at $1.03M in Q2 2016.
422 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2016.

Based on Gardner Lewis Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.